Opinion|Videos|July 29, 2024
Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
2
As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning
3
New York Experts Push for Coordinated Obesity Care Teams
4
Grocery Assistance Benefit Linked to Fewer Diabetes Complications
5